Works about SODIUM-glucose cotransporter 2 inhibitors
Results: 2018
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation.
- Published in:
- Expert Review of Clinical Pharmacology, 2024, v. 17, n. 11, p. 1081, doi. 10.1080/17512433.2024.2421872
- By:
- Publication type:
- Article
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis.
- Published in:
- Expert Review of Clinical Pharmacology, 2024, v. 17, n. 10, p. 949, doi. 10.1080/17512433.2024.2399073
- By:
- Publication type:
- Article
Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities.
- Published in:
- Medical Journal of Australia, 2025, v. 222, n. 1, p. 53, doi. 10.5694/mja2.52540
- By:
- Publication type:
- Article
Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities.
- Published in:
- Medical Journal of Australia, 2025, v. 222, n. 1, p. 52, doi. 10.5694/mja2.52541
- By:
- Publication type:
- Article
Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 2, p. 515, doi. 10.1002/cpt.3480
- By:
- Publication type:
- Article
Severe hypoglycaemia and diabetic ketoacidosis in adults presenting to a hospital emergency department: Adverse prognostic markers for survival in type 2 diabetes and the role of SGLT2 inhibitors.
- Published in:
- Diabetic Medicine, 2025, v. 42, n. 3, p. 1, doi. 10.1111/dme.15466
- By:
- Publication type:
- Article
A special issue on from bench to bedside: An integrated and multidisciplinary approach to tackling diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2025, v. 42, n. 2, p. 1, doi. 10.1111/dme.15501
- By:
- Publication type:
- Article
Pathophysiology of vascular ageing and the effect of novel cardio‐renal protective medications in preventing progression of chronic kidney disease in people living with diabetes.
- Published in:
- Diabetic Medicine, 2025, v. 42, n. 2, p. 1, doi. 10.1111/dme.15464
- By:
- Publication type:
- Article
Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD‐UKKA) guidelines.
- Published in:
- Diabetic Medicine, 2025, v. 42, n. 2, p. 1, doi. 10.1111/dme.15450
- By:
- Publication type:
- Article
O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy.
- Published in:
- Diabetic Medicine, 2025, v. 42, n. 2, p. 1, doi. 10.1111/dme.15436
- By:
- Publication type:
- Article
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.
- Published in:
- European Journal of Clinical Investigation, 2025, v. 54, n. 11, p. 1, doi. 10.1111/eci.70003
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter 2 inhibitors for all‐cause and cardiovascular death in people with different stages of CKD: A systematic review and meta‐analysis.
- Published in:
- European Journal of Clinical Investigation, 2025, v. 55, n. 2, p. 1, doi. 10.1111/eci.14335
- By:
- Publication type:
- Article
Серцева недостатність із збереженою фракцією викиду у хворих на цукровий діабет. Лікування інгібіторами натрій-глюкозного котранспортера-2.
- Published in:
- Family Medicine. European Practices / Sìmejna Medicina. Êvropejs'kì Praktiki, 2025, n. 1, p. 34, doi. 10.30841/2786-720X.1.2025.324230
- By:
- Publication type:
- Article
SGLT2i plus low calorie diet increases T2D remission rates.
- Published in:
- Practice Nurse, 2025, v. 55, n. 2, p. 5
- Publication type:
- Article
Impact of Sodium‐Glucose Co‐Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post‐Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis.
- Published in:
- Journal of Cardiovascular Electrophysiology, 2025, v. 36, n. 3, p. 673, doi. 10.1111/jce.16544
- By:
- Publication type:
- Article
Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1527972
- By:
- Publication type:
- Article
EARLY USE OF SGLT2 INHIBITORS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: QUANTITATIVE ANALYSIS OF CARDIAC BIOMARKERS, RENAL FUNCTION, AND IN-HOSPITAL MORTALITY.
- Published in:
- Environmental & Social Management Journal / Revista de Gestão Social e Ambiental, 2025, v. 19, n. 2, p. 1, doi. 10.24857/rgsa.v19n2-102
- By:
- Publication type:
- Article
Bridging cardiology and oncology in the era of precision medicine.
- Published in:
- Basic Research in Cardiology, 2025, v. 120, n. 1, p. 1, doi. 10.1007/s00395-025-01097-x
- By:
- Publication type:
- Article
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure.
- Published in:
- Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-93144-9
- By:
- Publication type:
- Article
Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product–receptor axis.
- Published in:
- Molecular Medicine, 2025, v. 31, n. 1, p. 1, doi. 10.1186/s10020-025-01138-0
- By:
- Publication type:
- Article
The Effect of SGLT-2 Inhibitors on Serum Potassium and Serum Sodium Levels in Diabetic Patients taking SGLT-2 Inhibitors, Reporting in A Tertiary Care Hospital, Rawalpindi.
- Published in:
- Pakistan Armed Forces Medical Journal, 2025, v. 75, n. 1, p. 142, doi. 10.51253/pafmj.v75i1.11954
- By:
- Publication type:
- Article
The 4S Pathway -- realigning management for older people with diabetes.
- Published in:
- Diabetes & Primary Care, 2025, v. 27, n. 1, p. 29
- By:
- Publication type:
- Article
Prescribing pearls: A guide to SGLT2 inhibitors.
- Published in:
- Diabetes & Primary Care, 2025, v. 27, n. 1, p. 7
- By:
- Publication type:
- Article
Weight loss drug hype grows.
- Published in:
- Diabetes & Primary Care, 2025, v. 27, n. 1, p. 1
- By:
- Publication type:
- Article
Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2025, v. 110, n. 3, p. e557, doi. 10.1210/clinem/dgae823
- By:
- Publication type:
- Article
Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product–receptor axis.
- Published in:
- Molecular Medicine, 2025, v. 31, n. 1, p. 1, doi. 10.1186/s10020-025-01138-0
- By:
- Publication type:
- Article
Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy.
- Published in:
- Diabetology & Metabolic Syndrome, 2025, v. 17, n. 1, p. 1, doi. 10.1186/s13098-025-01655-2
- By:
- Publication type:
- Article
Forxiga (Dapagliflozin): A Modern Approach to Managing Diabetes.
- Published in:
- African Journal of Diabetes Medicine, 2024, v. 32, n. 6, p. 4, doi. 10.54931/AJDM-32.6.3.
- By:
- Publication type:
- Article
Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China.
- Published in:
- Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1498927
- By:
- Publication type:
- Article
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials: Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults...: S. A. Shah et al
- Published in:
- Drugs & Aging, 2025, v. 42, n. 3, p. 195, doi. 10.1007/s40266-025-01183-8
- By:
- Publication type:
- Article
Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 4, p. 301, doi. 10.1177/10600280241277354
- By:
- Publication type:
- Article
The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.
- Published in:
- Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02643-6
- By:
- Publication type:
- Article
Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 65, doi. 10.1177/87551225241302731
- By:
- Publication type:
- Article
Successful renal replacement therapy of extreme ertugliflozin and alcohol induced euglycaemic ketoacidosis.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 3, p. 433, doi. 10.1007/s00592-024-02417-8
- By:
- Publication type:
- Article
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 3, p. 343, doi. 10.1007/s00592-024-02359-1
- By:
- Publication type:
- Article
Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 214, doi. 10.3390/ph18020214
- By:
- Publication type:
- Article
Renal Abscess Associated with SGLT2 Inhibitors Administration in Heart Failure Without Other Previous Risk Factors: A Case Report.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 389, doi. 10.3390/biomedicines13020389
- By:
- Publication type:
- Article
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1241, doi. 10.3390/jcm14041241
- By:
- Publication type:
- Article
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1048, doi. 10.3390/jcm14041048
- By:
- Publication type:
- Article
Sodium–Glucose Cotransporter 2 Inhibitors and Lower-Extremity Amputation: Is the Guilty Verdict Valid?
- Published in:
- Diabetes Care, 2025, v. 48, n. 3, p. 338, doi. 10.2337/dci24-0101
- By:
- Publication type:
- Article
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Advances in sodium-glucose transporter protein 2 inhibitors and tumors.
- Published in:
- Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1522059
- By:
- Publication type:
- Article
The Potential of SGLT2 Inhibitors to Counteract Anemia in Patients with Heart Failure: The Potential of SGLT2 Inhibitors to Counteract Anemia in Patients with Heart Failure: Kow et al.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis.
- Published in:
- Medicina (1010660X), 2025, v. 61, n. 2, p. 202, doi. 10.3390/medicina61020202
- By:
- Publication type:
- Article
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1670, doi. 10.3390/ijms26041670
- By:
- Publication type:
- Article
SGLT-2 inhibitors are beneficial in reducing the risk of thyroid cancer: findings from a Mendelian randomization study.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 2, p. 185, doi. 10.1007/s00592-024-02344-8
- By:
- Publication type:
- Article
Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2025, v. 197, n. 7, p. E178, doi. 10.1503/cmaj.240922
- By:
- Publication type:
- Article
Current updates of sodium-glucose cotransporter-2 inhibitor effects on atherosclerosis: a systematic review and meta-analysis of randomized controlled trial.
- Published in:
- Acta Angiologica, 2024, v. 30, n. 1, p. 1, doi. 10.5603/aa.98562
- By:
- Publication type:
- Article
Bexagliflozin in type 2 diabetes: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 7, p. 241, doi. 10.1007/s40267-024-01098-1
- By:
- Publication type:
- Article
Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure.
- Published in:
- Journal of Women's Health (15409996), 2023, v. 32, n. 11, p. 1219, doi. 10.1089/jwh.2023.0059
- By:
- Publication type:
- Article